Form 4: Quest Diagnostics Director, Denise M. Morrison, Reports Acquisition of Restricted Stock Units

Director Denise M. Morrison reports acquisition of 1,203 restricted stock units in Quest Diagnostics.

Summary

• On May 15, 2025, Denise M. Morrison, a director of Quest Diagnostics Inc., reported a transaction involving the company's common stock.
• Morrison acquired 1,203 shares of common stock through an award of restricted stock units.
• The price per share for the acquisition is $0.
• Following the transaction, Morrison beneficially owns 10,742 shares of Quest Diagnostics Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of stock acquisition. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The acquisition of restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's investment in the company.

Key Dates

Keywords

Quest Diagnostics, Director, Stock Acquisition, Restricted Stock Units, Beneficial Ownership, Form 4, DGX